To address this possibility we compared expression levels of the key kinases and two major negative regulators of the pathway, SPROUTY2 and RKIP, in the GHM vs. human melanoma cell lines with activated ERK1/2 due to oncogenic BRAF or NRAS mutations. The gene discussed is BRAF; the disease is melanoma.